1. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. 2003 Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res; 63:3886–90.
2. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. 2002 Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood; 100:2195–202.
3. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA. 1994 Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res; 54:2372–7.
4. Alsina M, Boyce BF, Mundy GR, Roodman GD. 1995 An in vivo model of human multiple myeloma bone disease. Stem Cells; 13 Suppl 2:48–50.
5. Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry Dt, Hamilton R, Halpern AC. 1997 Melanoma of unknown primary site: presentation, treatment, and prognosis – a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer; 79:1816–21.